What is this?
cGMP particle-size analysis measures particle-size distributions, typically by laser diffraction or microscopy/image analysis, under a controlled method suitable for release, stability, comparability, or transfer.
Start with the regulated decision
Develop, validate, verify, and transfer wet or dry particle-size methods for release and quality decisions.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.
Overview of cGMP Particle Size Analysis Services
When is it used?
Use it when particle size affects dissolution, bioavailability, content uniformity, flow, filtration, blend behavior, device performance, or batch disposition.
What are limitations?
Results depend strongly on dispersion medium, refractive index, obscuration, sonication, sample prep, agglomeration, shape, and wet/dry method choice.
What sample amounts are needed?
Method development and validation need more material than a one-time ID test because they require replicates, robustness, precision, intermediate precision, and sometimes transfer studies.
What techniques compete with it?
Competing or orthogonal methods include XRPD, Raman, FTIR, NMR, HPLC/GC, LC/MS, TGA/DSC, KF, particle-size analysis, microscopy, PLM, SEM/EDX, ICP-MS, and compendial tests depending on the quality attribute.
What does FDA care about?
FDA cares that the PSD method is specific to the intended distribution and that method parameters are controlled under USP <429>, <776>, <1174>, or other applicable expectations where relevant.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic uses cGMP particle-size analysis when particle-size distribution is part of a release, stability, comparability, process-control, or specification decision. Real-world applications include laser diffraction, microscopy, or sieve-based methods for APIs, excipients, and formulated materials where sampling, dispersion, method suitability, validation or verification, and controlled reporting determine whether the result can support quality decisions.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for cGMP Particle Size Analysis
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Laser diffraction PSD | Malvern Mastersizer 3000 v.3.70 with Malvern Access Configurator v.2.20 | Particle-size distribution by volume-equivalent sphere diameter; dry range 0.1-3500 um and wet range 0.01-1400 um. |
| cGMP PSD methods | Malvern Mastersizer 3000 platform with method-development, verification, transfer, validation, and release-testing workflows | Validated particle-size methods, batch release results, and cGMP/non-GMP comparability studies. |
| Morphologically directed Raman support | Renishaw inVia / Thermo FT-Raman / Ondax low-frequency Raman platforms; 785 nm, 1064 nm, and THz-Raman options | Particle-level chemistry and morphology correlation, MDRS-style component identification, and composition of selected particle populations. |
| Optical and digital morphology | Leica M80, Leica DM2500P, Keyence VHX-2000E, and Pax-it2! v.1.4.3 software | Particle-shape, agglomeration, habit, and topography observations to complement laser diffraction. |
| SEM/EDX morphology | Thermo Phenom XL SEM/EDX and FEI Quanta 3D FEG | High-resolution particle morphology and elemental confirmation for particles, contaminants, and agglomerates. |
Laser Diffraction Particle-Size Method Development for cGMP Release
This example shows why particle-size methods used for cGMP release must control dispersion, obscuration, optical properties, and reporting metrics rather than relying on a single D50 value. A regulated particle-size program may include wet or dry particle-size analysis, particle distribution, counting, method development, verification, transfer, and release testing, including support for USP chapters covering laser diffraction, bulk/tapped density, crystallinity, microscopy, powder flow, and water-solid interactions.
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceThermal Analysis (TGA/DSC)
Use cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceRelease Testing Services
Use verified or validated methods to support batch disposition, CoA issuance, stability testing, and regulatory documentation.
View serviceCommon questions
When should cGMP Particle Size Analysis be run under cGMP?
Run the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
How much material should be submitted?
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.
Can Triclinic help choose the method?
Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.
What makes the result defensible?
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Do you develop, validate, and transfer methods?
Yes. Triclinic develops, validates, verifies, and transfers particle-size methods, including laser-diffraction and microscopy-based approaches where appropriate. Method development can address wet or dry dispersion, obscuration, refractive index, sonication, dispersant selection, sample preparation, replicate design, D10/D50/D90 reporting, robustness, intermediate precision, and transfer conditions for cGMP release or stability use.
What must be controlled in a cGMP particle-size method?
Dispersion medium, refractive index or optical model, obscuration, sonication, stirring, sample concentration, wetting, agglomeration, instrument alignment, background, replicate strategy, and reporting basis must be controlled as applicable.
Discuss cGMP testing requirements
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.